MedTrace Logo

Working Mechanisms and Effectiveness of IV Ketamine-assisted Psychotherapy on Depression in TRD Clients

NCT07706478 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2026-07-15

No results posted yet for this study

Summary

Ketamine-Assisted Psychotherapy (KAP) is an innovative treatment that combines intravenous ketamine with psychotherapy in a carefully monitored clinical setting. At Senz, this treatment is being evaluated in an open-label clinical trial for individuals with persistent depression who have not responded sufficiently to previous treatments. The combination of ketamine, psychological support, and integration sessions aims to promote emotional processing, psychological flexibility, and lasting therapeutic change.

Conditions

Sponsors & Collaborators

  • Radboud University Medical Center

    collaborator OTHER

  • Senz

    lead OTHER

Principal Investigators

  • Rutger Engels · Senz

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-01
Primary Completion
2033-01-31
Completion
2033-01-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07706478 on ClinicalTrials.gov